DelveInsight’s, “Moderate and Severe Chronic Kidney Disease Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Moderate and Severe Chronic Kidney Disease pipeline landscape. It covers the Moderate and Severe Chronic Kidney Disease pipeline drug profiles, including Moderate and Severe Chronic Kidney Disease clinical trials and nonclinical stage products. It also covers the Moderate and Severe Chronic Kidney Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Moderate and Severe Chronic Kidney Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Moderate and Severe Chronic Kidney Disease clinical trials studies, Moderate and Severe Chronic Kidney Disease NDA approvals (if any), and product development activities comprising the technology, Moderate and Severe Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Moderate and Severe Chronic Kidney Disease Pipeline Report
- DelveInsight’s Moderate and Severe Chronic Kidney Disease pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Moderate and Severe Chronic Kidney Disease treatment.
- The leading Moderate and Severe Chronic Kidney Disease Companies includes Reata Pharmaceuticals, KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, Boehringer Ingelheim, Cadila Healthcare Limited, AM-Pharma, DiaMedica Therapeutics, Allena Pharmaceuticals, AstraZeneca, Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Oisin Biotechnologies, and others.
- Promising Moderate and Severe Chronic Kidney Disease Pipeline Therapies includes Dulaglutide, Insulin glargine, BI 764198, Cinacalcet HCl, AST-120, KBP-5074 0.25 mg tablet, Paricalcitol, Omarigliptin, Glipizide, CR845 0.5 mg Oral Tablet, and others.
- The Moderate and Severe Chronic Kidney Disease companies and academics are working to assess challenges and seek opportunities that could influence Moderate and Severe Chronic Kidney Disease R&D. The Moderate and Severe Chronic Kidney Disease pipeline therapies under development are focused on novel approaches to treat/improve Moderate and Severe Chronic Kidney Disease.
To explore more information on the latest breakthroughs in the Moderate and Severe Chronic Kidney Disease Pipeline treatment landscape of the report, click here @ Moderate and Severe Chronic Kidney Disease Pipeline Outlook
Moderate and Severe Chronic Kidney Disease Overview
Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease. Patients feel unwell or have symptoms with mild-to-moderate chronic kidney disease that is, stages 1 to 3. Chronic kidney disease is usually diagnosed by the eGFR test before any symptoms develop. Symptoms tend to develop when chronic kidney disease becomes severe (stage 4) or worse. The symptoms at first tend to be vague and nonspecific, such as feeling tired, having less energy than usual and just not feeling well.
Latest Developmental Activities or News in the Moderate and Severe Chronic Kidney Disease Treatment Landscape
- In February 2023- Notalgia paresthetica is a common and underdiagnosed nerve ailment that causes a lingering itch in the upper back. FDA-approved medications that target this condition specifically are not yet available.
In March 2022, Reata Pharmaceuticals announced that it had submitted a New Drug Application (NDA) for bardoxolone methyl (bardoxolone), its leading product, to the FDA. Bardoxolone’s NDA application was supported by efficacy and safety clinical data from the multi-center, Phase III CARDINAL trial. Results showed that bardoxolone significantly improved glomerular filtration rate (GFR) compared to placebo, and its adverse events were mild and moderate.
For further information, refer to the detailed Moderate and Severe Chronic Kidney Disease Unmet Needs, Moderate and Severe Chronic Kidney Disease Market Drivers, and Moderate and Severe Chronic Kidney Disease Market Barriers, click here for Moderate and Severe Chronic Kidney Disease Ongoing Clinical Trial Analysis
Moderate and Severe Chronic Kidney Disease Emerging Drugs Profile
Bardoxolone methyl: Reata Pharmaceuticals
Bardoxolone methyl is an Nrf2 activator currently being investigated in clinical trials for the treatment of patients with different forms of chronic kidney disease. Inflammation—initiated by a variety of pathogenic processes, including diabetes, systemic hypertension, IgA deposition, and genetic mutations—drives kidney function decline. At the physiological level, chronic activation of pro-inflammatory pathways in the kidney cells leads to a reduction in the glomerular filtration rate (GFR).
KBP-5074: KBP Biosciences
KBP Biosciences’ lead product candidate, KBP-5074, is a potentially best-in-class, next-generation, non-steroidal MRA discovered and developed by KBP’s scientists, is being developed globally to initially treat Stage 3b/4, or moderate-to-severe, CKD patients with uncontrolled hypertension. KBP-5074 selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors, suggesting that KBP-5074 should be effective in blocking the hypertensive and renal tissue damaging effects of aldosterone with reduced risk of pro-diabetic and adverse endocrine effects. In clinical trials conducted to-date, it has demonstrated an ability to lower blood pressure without androgenic effects such as hirsutism, obesity and gynecomastia. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Uncontrolled Hypertension and Moderate or Severe CKD.
Ziltivekimab: Novo Nordisk
Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in Phase III stage of development to treat patients with moderate to severe chronic kidney disease.
CLBS201: Caladrius Biosciences
CLBS201, is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”) in patients not yet requiring dialysis. Based on a wealth of published preclinical and early clinical data, it appears that the innate ability of CD34+ cells to promote the growth of new microvasculature could be a means to attenuate the progression of the disease or even reverse the course of CKD. The company has initiated a Phase I/II proof-of-concept study of CLBS201 in a moderate to severe CKD population.
Moderate and Severe Chronic Kidney Disease Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Moderate and Severe Chronic Kidney Disease. The companies which have their Moderate and Severe Chronic Kidney Disease drug candidates in the most advanced stage, i.e. preregistration include, Reata Pharmaceuticals.
Request a sample and discover the recent advances in Moderate and Severe Chronic Kidney Disease Ongoing Clinical Trial Analysis and Medications, click here @ Moderate and Severe Chronic Kidney Disease Treatment Landscape
Scope of the Moderate and Severe Chronic Kidney Disease Pipeline Report
- Coverage- Global
- Moderate and Severe Chronic Kidney Disease Companies- Reata Pharmaceuticals, KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, Boehringer Ingelheim, Cadila Healthcare Limited, AM-Pharma, DiaMedica Therapeutics, Allena Pharmaceuticals, AstraZeneca, Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Oisin Biotechnologies, and others
- Moderate and Severe Chronic Kidney Disease Pipeline Therapies- Dulaglutide, Insulin glargine, BI 764198, Cinacalcet HCl, AST-120, KBP-5074 0.25 mg tablet, Paricalcitol, Omarigliptin, Glipizide, CR845 0.5 mg Oral Tablet, and others.
- Moderate and Severe Chronic Kidney Disease Pipeline Therapies- Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Moderate and Severe Chronic Kidney Disease Market Drivers and Moderate and Severe Chronic Kidney Disease Market Barriers, click here @ Moderate and Severe Chronic Kidney Disease Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Moderate and Severe Chronic Kidney Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Moderate and Severe Chronic Kidney Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Bardoxolone Methyl: Reata Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Runcaciguat: Bayer
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- CLBS201: Caladrius Biosciences
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- UNI-494: Unicycive Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Moderate and Severe Chronic Kidney Disease Key Companies
- Moderate and Severe Chronic Kidney Disease Key Products
- Moderate and Severe Chronic Kidney Disease- Unmet Needs
- Moderate and Severe Chronic Kidney Disease- Market Drivers and Barriers
- Moderate and Severe Chronic Kidney Disease- Future Perspectives and Conclusion
- Moderate and Severe Chronic Kidney Disease Analyst Views
- Moderate and Severe Chronic Kidney Disease Key Companies
- Appendix
Got Queries? Find out the related information on Moderate and Severe Chronic Kidney Disease Mergers and acquisitions, Moderate and Severe Chronic Kidney Disease Licensing Activities @ Moderate and Severe Chronic Kidney Disease Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services